Dipeptide diaminobutyroyl benzylamide diacetate is a small synthetic peptide used as a cosmetic ingredient and sold by dsm-firmenich as SYN-AKE. Its maker says it mimics Waglerin-1, a peptide from temple viper venom. This guide covers its structure, proposed mechanism, research and regulatory status. Sources were checked on November 17, 2026.
Quick answer: This ingredient, often called SYN-AKE, is a three-unit peptide-like molecule with a benzylamide end. Its manufacturer says it reversibly blocks the muscle-type nicotinic acetylcholine receptor in laboratory tests. Published research is limited to computer modeling, cell tests and one multi-ingredient clinical study. It is a cosmetic ingredient, not a drug, and we found no Cosmetic Ingredient Review safety assessment for it.
Vitrapep does not sell dipeptide diaminobutyroyl benzylamide diacetate; this page is a reference summary of published research and regulatory information.
What is dipeptide diaminobutyroyl benzylamide diacetate?
The long name is an INCI name, the standard name used on cosmetic ingredient lists. CosIng, the European Commission’s cosmetic ingredient database, lists it as an active entry (CosIng, 2026). PubChem gives its structure as H-β-Ala-Pro-Dab-NH-Bzl with two acetic acid molecules (PubChem CID 71465152).
Read against that structure, the name works like a parts list. “Dipeptide” is beta-alanine joined to proline. “Diaminobutyroyl” is a third unit, 2,4-diaminobutyric acid (Dab). “Benzylamide” is a benzyl group capping the end. “Diacetate” means the molecule is a salt with two acetic acids.
PubChem lists the formula as C23H37N5O7 and the molecular weight as 495.6 g/mol for this salt form. The manufacturer calls it a “synthetic tripeptide with mol weight below 500 Da” (dsm-firmenich). Our peptide primer explains how amino acids link into peptides.
PubChem lists Syn-ake among its synonyms. The dsm-firmenich product page gives SYN-AKE’s INCI listing as glycerin, water and dipeptide diaminobutyroyl benzylamide diacetate. A 2025 review credits the original SYN-AKE to Pentapharm of Basel, Switzerland (Zdrada-Nowak et al., 2025).
Dipeptide diaminobutyroyl benzylamide diacetate: key facts
| Fact | Detail |
|---|---|
| INCI name | Dipeptide Diaminobutyroyl Benzylamide Diacetate |
| Structure type | Synthetic peptide-like molecule; three amino-acid units with a benzylamide end; diacetate salt |
| Sequence | H-β-Ala-Pro-Dab-NH-Bzl · 2 acetic acid |
| Molecular formula | C23H37N5O7 (diacetate salt) |
| Molecular weight | 495.6 g/mol (diacetate salt) |
| Main cosmetic function (CosIng) | Skin conditioning |
| Trade name(s) | SYN-AKE (dsm-firmenich; originally Pentapharm) |
How does dipeptide diaminobutyroyl benzylamide diacetate work?
The manufacturer says it “mimics Waglerin-1 functionality, a peptide found in the venom of the temple viper.” It states that, in vitro, the ingredient acts as an antagonist at the muscle-type nicotinic acetylcholine receptor. In its words, “the muscular nicotinic ACh receptors are reversibly blocked, the ion channel remains closed” (dsm-firmenich).
Acetylcholine is the chemical messenger that tells muscle to contract. Blocking its receptor would, in this model, relax the muscle. A 2020 review describes the same model, citing DSM. It adds that it found no scientific papers on clinical studies of the molecule (Errante et al., 2020).
That review labels the molecule tripeptide-3. CosIng uses the INCI name Tripeptide-3 for a different peptide, one made of glycine, serine and valine. So the INCI name above is the safer label. For a different proposed mechanism, see our Argireline guide.
What is dipeptide diaminobutyroyl benzylamide diacetate used for?
CosIng lists one cosmetic function: skin conditioning. A skin-conditioning agent helps keep skin in good condition. The CosIng record links no annex of the EU Cosmetics Regulation and no scientific committee opinion to this ingredient.
The manufacturer markets SYN-AKE as reducing “the appearance of deep wrinkles.” That is a claim about appearance, not an FDA finding. The 2025 review lists SYN-AKE in a table of comparison peptides that also includes pentapeptide-18 (Leuphasyl). See our peptides in skincare overview for the wider field.
What does the research show?
Manufacturer studies. dsm-firmenich describes a placebo-controlled study of 100 volunteers, 25 per group, over 4 weeks. It also describes skin-roughness measures on crow’s feet after 28 days. The 2020 review, citing DSM, reports wrinkle visibility reduced by up to 52% after 28 days. We found no peer-reviewed report of these tests.
Gok 2024 (computer modeling and in vitro). Researchers in Istanbul modeled how SYN-AKE binds several skin proteins. Its strongest predicted binding was to SIRT1, at −9.32 kcal/mol. In lab tests, its antioxidant activity rose with concentration. The team also ran cell-toxicity and Ames genotoxicity tests, but the abstract does not give those results. Yildiz Technical University and TÜBİTAK, Turkey’s science agency, funded the work (Gok et al., 2024).
Gok 2026 (in vitro). The same group made a nanoemulsion containing SYN-AKE. In cell tests, they reported that it was not genotoxic, was compatible with cells, and inhibited collagenase. The abstract gives no numbers (Gok et al., 2026).
Zhu 2026 (ex vivo and human). L’Oréal scientists tested a serum combining this ingredient with acetyl hexapeptide-8, gluconolactone, niacinamide and laminaria extract. The authors reported that, in 50 people, static wrinkle scores improved 35% to 69% after 12 weeks. In 42 people, dynamic wrinkle scores improved 10% to 13%. L’Oréal funded the work, and the abstract describes no control group (Zhu et al., 2026).
Because the serum combined several actives, the Zhu study does not isolate this ingredient’s effect.
What safety data exist?
We found no Cosmetic Ingredient Review (CIR) safety assessment for dipeptide diaminobutyroyl benzylamide diacetate. CIR’s quick reference table, September 2020 edition, does not list it (CIR, 2020). Searches of the CIR website and PubMed found no later report. CosIng links no opinion from the EU Scientific Committee on Consumer Safety (SCCS).
The published safety data are laboratory tests. Gok 2024 ran Ames and cell-toxicity tests without stating results in the abstract. Gok 2026 reported that its nanoemulsion was not genotoxic. The Zhu abstract does not report adverse events.
What is dipeptide diaminobutyroyl benzylamide diacetate’s regulatory status, and how is it used in research?
Dipeptide diaminobutyroyl benzylamide diacetate is a cosmetic ingredient, not an FDA-approved drug. FDA states that cosmetic products and ingredients, except color additives, “do not need FDA premarket approval” (FDA, 2025). Products meant to treat or prevent disease are drugs (FDA, 2024).
Congress enacted the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) on December 29, 2022 (FDA, 2026). It requires facility registration, product listing, serious adverse event reports within 15 business days, and safety records (FDA MoCRA page).
In published research, the ingredient appears in computer modeling and cell studies, and in one industry clinical study of a multi-ingredient serum.
Frequently asked questions about dipeptide diaminobutyroyl benzylamide diacetate
Is it the same as SYN-AKE?
SYN-AKE is the dsm-firmenich trade name for an ingredient solution whose INCI listing includes dipeptide diaminobutyroyl benzylamide diacetate. PubChem also lists Syn-ake as a synonym.
Does it contain snake venom?
No. It is made synthetically. The manufacturer says it mimics the function of Waglerin-1, a venom peptide.
Why is it called a dipeptide if the maker calls it a tripeptide?
The INCI name counts beta-alanine and proline as the dipeptide, then names diaminobutyric acid separately. The maker counts all three units.
Is it FDA-approved?
No. It is a cosmetic ingredient. US cosmetic ingredients, other than color additives, do not need FDA premarket approval.
Has it been tested alone in people?
Not in any peer-reviewed study we found. The one published human study tested a serum with several actives.
What to know now
- Identity: β-Ala-Pro-Dab benzylamide, diacetate salt; trade name SYN-AKE; 495.6 g/mol.
- CosIng function: skin conditioning.
- Mechanism: manufacturer reports reversible blocking of the muscle-type acetylcholine receptor in vitro.
- Evidence: modeling and cell studies, plus one L’Oréal study of a multi-ingredient serum.
- Safety: no CIR or SCCS assessment found; only laboratory safety tests published.
- Status: cosmetic ingredient; not an FDA-approved drug.
What we’re watching
FDA’s ongoing MoCRA rollout, tracked on its MoCRA page. Any CIR review of this ingredient, which would appear on cir-safety.org. Related guides: Argireline, acetyl octapeptide-3 and pentapeptide-18.